生存期-话题@MedSci

#生存期#

350篇内容 | 2797人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1378288, encodeId=e0e913e8288d8, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Br J Cancer：体重指数（BMI）和**淋巴细胞计数（ALC）：乳腺癌患者无病生存期的预测指标, objectType=article, longId=210681, objectId=28ad210681eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28ad210681eb, replyNumber=0, likeNumber=133, createdTime=2021-05-01, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28ad210681eb, moduleTitle=Br J Cancer：体重指数（BMI）和**淋巴细胞计数（ALC）：乳腺癌患者无病生存期的预测指标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28ad210681eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378287, encodeId=f0d213e8287e6, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Brit J Cancer：体重指数和**淋巴细胞计数可预测乳腺癌患者无病生存期, objectType=article, longId=210269, objectId=f97e210269dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f97e210269dd, replyNumber=0, likeNumber=160, createdTime=2021-04-23, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f97e210269dd, moduleTitle=Brit J Cancer：体重指数和**淋巴细胞计数可预测乳腺癌患者无病生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f97e210269dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378286, encodeId=737c13e8286fb, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Eur Radiol:对于HCC患者生存期的预测，影像学表现也许更重要, objectType=article, longId=210100, objectId=8451210100cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8451210100cd, replyNumber=0, likeNumber=55, createdTime=2021-04-19, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8451210100cd, moduleTitle=Eur Radiol:对于HCC患者生存期的预测，影像学表现也许更重要, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8451210100cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378285, encodeId=153813e828555, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=JAMA Surg：肝移植 vs 门静脉栓塞术后肝切除对高肿瘤负担的结肠癌肝转移患者生存期的影响, objectType=article, longId=209997, objectId=024120999e3b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=024120999e3b, replyNumber=0, likeNumber=56, createdTime=2021-04-16, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=024120999e3b, moduleTitle=JAMA Surg：肝移植 vs 门静脉栓塞术后肝切除对高肿瘤负担的结肠癌肝转移患者生存期的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=024120999e3b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378284, encodeId=476713e8284c9, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Lancet Oncol：积极症状控制联合FOLFOX化疗可有效延长二线治疗晚期胆道癌患者生存期, objectType=article, longId=209579, objectId=b43d2095e9ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b43d2095e9ba, replyNumber=0, likeNumber=113, createdTime=2021-04-06, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b43d2095e9ba, moduleTitle=Lancet Oncol：积极症状控制联合FOLFOX化疗可有效延长二线治疗晚期胆道癌患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b43d2095e9ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378283, encodeId=8b4b13e828375, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=SOLO2/ENGOT-Ov21试验终分析：奥拉帕利维持治疗卵巢癌总生存期与安慰剂相比无统计学差异！, objectType=article, longId=208701, objectId=790a208e01b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=790a208e01b0, replyNumber=0, likeNumber=67, createdTime=2021-03-21, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=790a208e01b0, moduleTitle=SOLO2/ENGOT-Ov21试验终分析：奥拉帕利维持治疗卵巢癌总生存期与安慰剂相比无统计学差异！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=790a208e01b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378281, encodeId=fad513e82814e, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Eur Radiol:用磁共振来评价骨肿瘤的化疗效果并评价生存期, objectType=article, longId=208338, objectId=09f620833804, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09f620833804, replyNumber=0, likeNumber=74, createdTime=2021-03-15, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09f620833804, moduleTitle=Eur Radiol:用磁共振来评价骨肿瘤的化疗效果并评价生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=09f620833804)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378282, encodeId=b07e13e82820f, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=“T+A”方案显著改善晚期肝癌患者总生存期，邢宝才教授解读IMbrave150全新结果丨ASCO GI, objectType=article, longId=208095, objectId=2339208095d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2339208095d3, replyNumber=0, likeNumber=72, createdTime=2021-03-09, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2339208095d3, moduleTitle=“T+A”方案显著改善晚期肝癌患者总生存期，邢宝才教授解读IMbrave150全新结果丨ASCO GI, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2339208095d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378280, encodeId=706d13e8280ca, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Neuro Oncol：激素治疗会恶化脑转移癌患者的总生存期和无进展生存期！, objectType=article, longId=207681, objectId=b94020e681d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b94020e681d7, replyNumber=0, likeNumber=75, createdTime=2021-02-28, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b94020e681d7, moduleTitle=Neuro Oncol：激素治疗会恶化脑转移癌患者的总生存期和无进展生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b94020e681d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378279, encodeId=a4d713e827907, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Eur Radiol：如何使用放射组学提高预测胶质母细胞瘤患者生存期？, objectType=article, longId=207602, objectId=ee1f20e602d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee1f20e602d9, replyNumber=0, likeNumber=85, createdTime=2021-02-27, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee1f20e602d9, moduleTitle=Eur Radiol：如何使用放射组学提高预测胶质母细胞瘤患者生存期？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee1f20e602d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378278, encodeId=10a713e8278d5, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Ilixadencel治疗肾癌，患者生存期得以显著延长, objectType=article, longId=207492, objectId=637c20e4923d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=637c20e4923d, replyNumber=0, likeNumber=65, createdTime=2021-02-24, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=637c20e4923d, moduleTitle=Ilixadencel治疗肾癌，患者生存期得以显著延长, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=637c20e4923d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378276, encodeId=c3e713e8276c0, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=JCO：来那度胺联合R-CHOP治疗可延长未经治疗的弥漫性大B细胞淋巴瘤患者的生存期, objectType=article, longId=207011, objectId=dcad20e01104, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcad20e01104, replyNumber=0, likeNumber=102, createdTime=2021-02-11, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcad20e01104, moduleTitle=JCO：来那度胺联合R-CHOP治疗可延长未经治疗的弥漫性大B细胞淋巴瘤患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dcad20e01104)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378277, encodeId=d95813e8277f7, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=欧狄沃辅助治疗肌层浸润性尿路上皮癌延长患者无病生存期近2倍, objectType=article, longId=206995, objectId=c74f20699566, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c74f20699566, replyNumber=0, likeNumber=59, createdTime=2021-02-10, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c74f20699566, moduleTitle=欧狄沃辅助治疗肌层浸润性尿路上皮癌延长患者无病生存期近2倍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c74f20699566)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378275, encodeId=335e13e827518, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=2020世界肺癌大会：Keytruda联合化疗使晚期NSCLC生存期翻倍, objectType=article, longId=206761, objectId=2de1206e6140, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2de1206e6140, replyNumber=0, likeNumber=123, createdTime=2021-02-05, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2de1206e6140, moduleTitle=2020世界肺癌大会：Keytruda联合化疗使晚期NSCLC生存期翻倍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2de1206e6140)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378274, encodeId=a3ef13e8274e1, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=WCLC 2020：Tagrisso可显著延长EGFR突变非小细胞肺患者的无病生存期, objectType=article, longId=206510, objectId=103720651045, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=103720651045, replyNumber=0, likeNumber=59, createdTime=2021-02-02, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=103720651045, moduleTitle=WCLC 2020：Tagrisso可显著延长EGFR突变非小细胞肺患者的无病生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=103720651045)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378273, encodeId=612313e827340, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=邢宝才教授：生存期翻倍，“T+A”免疫联合治疗推动晚期肝癌系统性治疗获得飞跃, objectType=article, longId=206321, objectId=461320632130, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=461320632130, replyNumber=0, likeNumber=80, createdTime=2021-01-29, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=461320632130, moduleTitle=邢宝才教授：生存期翻倍，“T+A”免疫联合治疗推动晚期肝癌系统性治疗获得飞跃, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=461320632130)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378272, encodeId=4a3713e82721f, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=宫颈癌 || 微创根治性子宫切除术的无病生存期, objectType=article, longId=206057, objectId=0a7320605e23, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a7320605e23, replyNumber=0, likeNumber=54, createdTime=2021-01-24, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a7320605e23, moduleTitle=宫颈癌 || 微创根治性子宫切除术的无病生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a7320605e23)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378271, encodeId=1ad113e82719a, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=罗氏公布IMbrave150研究主要终点全新结果：“T+A”方案可显著改善晚期肝癌患者总生存期，中国数据表现尤佳, objectType=article, longId=205617, objectId=b61a20561e2a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b61a20561e2a, replyNumber=0, likeNumber=74, createdTime=2021-01-12, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b61a20561e2a, moduleTitle=罗氏公布IMbrave150研究主要终点全新结果：“T+A”方案可显著改善晚期肝癌患者总生存期，中国数据表现尤佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b61a20561e2a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378270, encodeId=3d6113e8270b4, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Eur Radiol：利用MRI纹理分析来识别肝内胆管细胞癌免疫表型并预测生存期, objectType=article, longId=205354, objectId=215020535407, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=215020535407, replyNumber=0, likeNumber=66, createdTime=2021-01-07, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=215020535407, moduleTitle=Eur Radiol：利用MRI纹理分析来识别肝内胆管细胞癌免疫表型并预测生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=215020535407)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378269, encodeId=cf8713e8269af, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Lancet子刊：卡瑞利珠单抗创非鳞NSCLC最长总生存期, objectType=article, longId=205124, objectId=5108205124d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5108205124d2, replyNumber=0, likeNumber=81, createdTime=2021-01-02, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5108205124d2, moduleTitle=Lancet子刊：卡瑞利珠单抗创非鳞NSCLC最长总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5108205124d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

生存期

2020-05-29

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Br J Cancer：体重指数（BMI）和**淋巴细胞计数（ALC）：乳腺癌患者无病生存期的预测指标

2021-05-01

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Brit J Cancer：体重指数和**淋巴细胞计数可预测乳腺癌患者无病生存期

2021-04-23

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Eur Radiol:对于HCC患者生存期的预测，影像学表现也许更重要

2021-04-19

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

JAMA Surg：肝移植 vs 门静脉栓塞术后肝切除对高肿瘤负担的结肠癌肝转移患者生存期的影响

2021-04-16

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Lancet Oncol：积极症状控制联合FOLFOX化疗可有效延长二线治疗晚期胆道癌患者生存期

2021-04-06

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

SOLO2/ENGOT-Ov21试验终分析：奥拉帕利维持治疗卵巢癌总生存期与安慰剂相比无统计学差异！

2021-03-21

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Eur Radiol:用磁共振来评价骨肿瘤的化疗效果并评价生存期

2021-03-15

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

“T+A”方案显著改善晚期肝癌患者总生存期，邢宝才教授解读IMbrave150全新结果丨ASCO GI

2021-03-09

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Neuro Oncol：激素治疗会恶化脑转移癌患者的总生存期和无进展生存期！

2021-02-28

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Eur Radiol：如何使用放射组学提高预测胶质母细胞瘤患者生存期？

2021-02-27

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Ilixadencel治疗肾癌，患者生存期得以显著延长

2021-02-24

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

JCO：来那度胺联合R-CHOP治疗可延长未经治疗的弥漫性大B细胞淋巴瘤患者的生存期

2021-02-11

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

欧狄沃辅助治疗肌层浸润性尿路上皮癌延长患者无病生存期近2倍

2021-02-10

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

2020世界肺癌大会：Keytruda联合化疗使晚期NSCLC生存期翻倍

2021-02-05

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

WCLC 2020：Tagrisso可显著延长EGFR突变非小细胞肺患者的无病生存期

2021-02-02

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

邢宝才教授：生存期翻倍，“T+A”免疫联合治疗推动晚期肝癌系统性治疗获得飞跃

2021-01-29

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

宫颈癌 || 微创根治性子宫切除术的无病生存期

2021-01-24

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

罗氏公布IMbrave150研究主要终点全新结果：“T+A”方案可显著改善晚期肝癌患者总生存期，中国数据表现尤佳

2021-01-12

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Eur Radiol：利用MRI纹理分析来识别肝内胆管细胞癌免疫表型并预测生存期

2021-01-07

一叶知秋 (审核中...)

前往app查看评论内容

#生存期#

Lancet子刊：卡瑞利珠单抗创非鳞NSCLC最长总生存期

2021-01-02

科室
- - 订阅+
  - 更多科室
工具
服务